Navigation Links
InterMune to Present at the SIGnificant Options in Healthcare Conference
Date:2/28/2008

BRISBANE, Calif., Feb. 28 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at Susquehanna's Second Annual SIGnificant Options in Healthcare Conference in New York on March 5, 2008 at 2:30 p.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (R7227) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

Except for the historical information contained herein, this press release contains ce
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
7. Avicena Group to Present at Noble Financial Conference
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CEL-SCI to Present at the Noble Financial Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., A mechanised blue dye ...tion to packaging quality assurance one step close...on-contact leak testing machine developed by Se... been installed in several local and global pharma... to address quality assurance and productivity imp...
(Date:11/25/2009)..., Ambassador to Speak at ... Toronto, Canada (Vocus) November 25, 2009 -- Amba..., ,Who: ,David Appia, French Ambassador for Intern...vest in France Agency ,To view a biography of Davi...: ,Ambassador Appia is available to meet with pres...
(Date:11/25/2009)...,, NEWYORK,Nov.25/PRNewswire/--Reportlinker....einitscatalogue: ,, BrazilBioethanolMarketAnal...nker.com/p0165503/Brazil-Bioethanol-Market-Analysi...olMarketAnalysisandForecaststo2013 ,, Summary ...tsoftheglobalbioethanolmarketandtheBrazilbioethano...
(Date:11/24/2009)..., Ambassador to also Visi...ber 24, 2009 -- , , ,Who: David Appia, French Amba...and CEO of the Invest in France Agency, , , , ,Wh...ss to discuss recent pro-business initiatives adop...scal and academic landscape for innovation and dev...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3French Ambassador for International Investment to Visit Toronto December 11 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9
...USTIN, Calif., Feb. 12 Peregrine,Pharmaceuticals,...ceutical,company developing targeted therapies for...ection (HCV), today announced that patient dosing ...te the safety and efficacy of,bavituximab in combi...,breast cancer. The primary objective of the study...
...LAREMONT, Calif., Feb. 12 Keck Graduate Institute...dent and CEO of the,Biotechnology Industry Organiz...e System & the Presidential Race: Who Will Regulat...o Distinguished Lecture Series on,Wednesday, March... that Jim Greenwood will serve as our guest,speake...
...ecent Product Introductions Drive 49% Revenue Grow... 66%, WESTFORD, Mass., Feb. 12 Cynosure, In...acturer of a broad array of,light-based aesthetic ...,and net income for the quarter and year ended Dec...sults, Revenues increased 49% to $36.6 million in...
Other Biology Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 4KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 2KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 3Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 2Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 3Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 4Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 5Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 6Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 7Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 8Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 9Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 10Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 11Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 12
(Date:11/25/2009)...vital to your health as what you eat, found resear.... Their experiments in mice revealed that the dail...iverthe body,s metabolic clearinghouseis mostly co...adian clock as conventional wisdom had it. , "I...number of genes completely independent of the circ...
(Date:11/24/2009)...amed 12 new grant recipients for 2009. The awards,...across a broad spectrum of lupus research. All wer...ntial to drive scientific discovery to ultimately ...stemic lupus. , The 2009 grants go to both new a... and include interdisciplinary and highly promisin...
(Date:11/24/2009)...t may help gut bacteria bind to the gastrointestin...roducers to identify strains that are likely to be... interact with cells lining the gut to have a bene...he gut they are more likely to stick around long e...uge from the Institute of Food Research. IFR is a...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A sticky solution for identifying effective probiotics 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 1Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 3Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 4Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 5Winner Medical One for Two Reverse Stock Split Becomes Effective and Begins Trading Under New Symbol 3A WWIN 58965 1Winner Medical One for Two Reverse Stock Split Becomes Effective and Begins Trading Under New Symbol 3A WWIN 58965 2Blue Cross and Blue Shield Companies Honored for Innovative Programs That Help Consumers Live Healthier Lives 58963 1Blue Cross and Blue Shield Companies Honored for Innovative Programs That Help Consumers Live Healthier Lives 58963 2
...sease and drug addiction are polar opposite diseas...rkinson,s patients don,t have enough of it; drug a... of dopamine in these disorders has been well know...earch from Northwestern University,s Feinberg Scho...ens and weakens the two primary circuits in the br...
...who has ever tried smoking probably remembers that...ave of nausea or a nasty coughing fit. For others,...re or "buzz." , Now, a new study links those firs...t a person is currently a smoker, to a particular ...e path that leads from that first cigarette to lif...
...n Beijing kicks off this week, the event is giving...serve how the atmosphere responds when a heavily p...trial emissions. , The National Science Foundatio..." (CAPMEX) will include a series of flights by spe...ous unmanned aerial vehicles (AUAVs). , The aeri...
Other Biology News:Unlocking mystery of why dopamine freezes Parkinson's patients 2Unlocking mystery of why dopamine freezes Parkinson's patients 3If your first cigarette gave you a buzz and you now smoke, a gene may be to blame 2If your first cigarette gave you a buzz and you now smoke, a gene may be to blame 3Scientists to assess Beijing Olympics air pollution control efforts 2Scientists to assess Beijing Olympics air pollution control efforts 3
... benchmark for analytical performance , When yo...al,performance, the Varian 810-MS delivers.,,... collisional interface/extraction optics minimize,...e level,quantification. , Optimized sample in...
...tical to the DH-2000, except that it uses a deep-U...elength range and comes with a shutter (controlled...000 Deuterium Tungsten Halogen Light Source combin...en halogen light sources in a single optical path....
...el's depleted sera are specifically depleted of a ...he depleted protein, the alternative and classical...efore ideal for the detection and quantitation of ...ted sera have been used to assess complement activ...
...tical to the D-2000, except that it uses a deep-UV...ength range and comes with a shutter (controlled v...Light Source produces a powerful, stable output fr...e light source are available, providing a waveleng...
Biology Products: